TSXV:CLAS.H - Post by User
Post by
Captainblkon Dec 18, 2019 7:45pm
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
52 Views
Post# 30470701
KLY Holds a Niche Leadership in GVHD
KLY Holds a Niche Leadership in GVHDKalytera is the exclusive licensee of two issued U.S. patents covering the use of CBD in the prevention and treatment of GVHD, and is also the exclusive licensee of pending patent applications in other jurisdictions for the use of CBD in the prevention and treatment of GVHD, including a EU patent application. The European Patent Office has issued a Notice of Allowance for the EU patent application, and the patent is expected to issue early next quarter. In addition to these patents and patent applications, the Company has also obtained four orphan drug designations for the treatment and prevention of GVHD in the U.S. and Europe. Such orphan drug designations will provide 7-years of market exclusivity in the U.S., and 10-years of market exclusivity in the E.U., upon regulatory approval of the Companys CBD products for the prevention and/or treatment of acute GVHD.